Two products are available for the prevention of HAV infection: hepatitis A vaccine and immune globulin (IG) for intramuscular (IM) administration.  Administered IM in a 2-dose series at 0 and 6--12 months, these vaccines induce protective antibody levels in virtually all adults. By 1 month after the first dose, 94%--100% of adults have protective antibody levels; 100% of adults develop protective antibody after a second dose. IG is a sterile solution of concentrated immunoglobulins which, when administered IM before or within 2 weeks after exposure to HAV, is >85% effective in preventing HAV infections. Vaccination is the most effective means of preventing HAV transmission among persons at risk for infection (e.g., MSM, illegal drug users, and persons with chronic liver disease).  Because transmission of HAV during sexual activity probably results from fecal-oral contact, measures typically used to prevent the transmission of other sexually transmitted disease (e.g., use of condoms) do not prevent HAV transmission.
Hepatitis A primary prevention
Hepatitis E primary prevention
Hepatitis C primary prevention
Hepatitis B primary prevention
Hepatitis A secondary prevention
Hepatitis B secondary prevention
Hepatitis C secondary prevention
Hepatitis B future or investigational therapies